Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Antengene (6996 HK)
Watchlist
44
Analysis
Health Care
•
China
Antengene Corporation Limited operates as a specialty pharmaceutical company. The Company produces innovative drugs, selinexor, eltanexor, verdinexor, and other products. Antengene provides its services throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Zhejiang Leapmotor Technologie
•
03 Oct 2022 05:58
HSCI Index Rebalance and Stock Connect: Potential Changes in December & March (There's a Lot!)
There could be 3 adds in December while there will be MANY more changes in March. The adds should outnumber the deletes, but there will be many...
Brian Freitas
Follow
551 Views
Share
bullish
•
Quantitative Analysis
•
17 Sep 2022 15:56
Hong Kong Connect Flows (Sep 16th): Chinese Buying Wuxi Biologics After Biden's New Executive Order
We analyzed Hong Connect flows last week and highlight Chinese purchase of Wuxi Biologics post new executive order signed on Monday.
Ke Yan, CFA, FRM
Follow
358 Views
Share
bearish
•
Thematic (Sector/Industry)
•
07 Nov 2021 09:23
China Healthcare Weekly (Nov.5) - Final Two Domestic Policy Risks, Outlook of China CXO Industry
The insight mainly analyzed the final two domestic policy risks (the national medical insurance negotiation & the VBP on insulin) by the end of...
Xinyao (Criss) Wang
Follow
225 Views
Share
bullish
•
Capitaland
•
25 Jul 2021 07:04
Last Week in Event SPACE: Capitaland, Boral, Milton/WHSP, Santos/Oil Search, Education Profit Ban
The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...
David Blennerhassett
Follow
355 Views
Share
bearish
•
Antengene
•
20 May 2021 07:18
Antengene (6996.HK) - Still Has a Long Way to Go Despite the New Progress On Selinexor
Based on the new progress of the core product candidate ATG-010 (selinexor, XPOVIO), this article analyzed the business prospects, concerns and...
Xinyao (Criss) Wang
Follow
235 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.39.3
x